SCHEMBL23383769

SCHEMBL23383769

C=C(CCNC(=O)COc1ccc(Cl)cc1)NC(=O)COC1CC1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ATF4 P18848 7/20 0.58
▸ KDM4E B2RXH2 1/20 0.48
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ SENP2 Q9HC62 1/20 0.44
▸ SENP1 Q9P0U3 1/20 0.44
▸ BCHE P06276 2/20 0.44
▸ ACHE P22303 2/20 0.44
▸ TDP1 Q9NUW8 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ FAAH O00519 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23332791 0.96 ATF4 (0.60) ATF4KDM4EMEN1KMT2ACYP1A2
SCHEMBL23383657 0.96 ATF4 (0.60) ATF4KDM4EMEN1KMT2ACYP1A2
SCHEMBL23384143 0.95 ATF4 (0.59) ATF4KDM4EMEN1KMT2ACYP1A2
SCHEMBL23332720 0.89 ATF4 (0.47) ATF4KDM4EMEN1KMT2ACYP1A2
SCHEMBL23182908 0.89 KDM4E (0.54) ATF4KDM4EMEN1KMT2ACYP1A2
SCHEMBL23332739 0.89 ATF4 (0.47) ATF4KDM4EMEN1KMT2ACYP1A2
SCHEMBL23332725 0.89 ATF4 (0.48) ATF4KDM4EMEN1KMT2ACYP1A2
SCHEMBL25962498 0.89 ATF4 (0.48) ATF4KDM4EMEN1KMT2ACYP1A2
SCHEMBL23332793 0.89 ATF4 (0.48) ATF4KDM4EMEN1KMT2ACYP1A2
SCHEMBL23383730 0.86 ATF4 (0.59) ATF4KDM4EMEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210145771-A1 N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1] PENTAN-1-YL)-2-CYCLOBUTANE-1- CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-05-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210145771-A1 N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1] PENTAN-1-YL)-2-CYCLOBUTANE-1- CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES ATF4, EIF2B1, EIF4A1 ATF4 1/4885KDM4E 2283/4885MEN1 4354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback